On HEMEX’s Investment Showcase today we tackled the pain, bleeding, and tissue tear that women worldwide experience when undergoing common gynaecological procedures. Our portfolio company ASPIVIX is developing the next-generation suction-based cervical device that will improve these traumatic experiences.
Investment Press Release
hemotune makes a significant step forward: advancing into clinical trials after completing CHF 14 million Series B2 round
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Diversity Hemex Team
We welcome David to the team!
HEMEX contribution for preparing tomorrow's leaders!
Continue reading
Investment Press Release
Driving the future of non-surgical endometriosis diagnosis: Hera Biotech acquires Scailyte’s endometriosis diagnostic assets
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
Hemex Team
Graphic Design Internship at HEMEX
Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing [...]
Continue reading
Hemex Team Press Release
HEMEX opens subsidiary in Belgium, expanding its presence in the EU
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the [...]
Continue reading
We are thrilled to announce the successful completion of an oversubscribed Series C to further accelerate our company’s growth.
This unique event has aired online throughout the whole day today. 60 start-ups have pitched their ideas at this impressive 2021 Selection Day. Some things don’t change even in the middle of a pandemic, and like every year, at HEMEX, we were very impressed with the projects presented. We are proud to claim that the swiss start-up ecosystem has a lot to offer to the world!
HEMEX is delighted to announce our exciting new partnership with SMART-TRIAL. Collecting and managing clinical data has been revolutionized for the MedTech industry and we are pleased that eCRF, eConsent, and more can now be done with confidence. This partnership enables us to provide healthcare start-ups with a complete range of packages to ensure conducting clinical trials, PMCF studies, and monitoring is made easy and affordable.
HEMEX’s Investment Showcase featured today TOM Medications. The digital health company has developed the app that will make easier the lives of millions of patients with chronic diseases at an early stage.
The final 3 steps that will enable you to conclude your clinical development process. Find out how can you thoroughly REPORT your study results with HEMEX Contract Research Organization!
Galventa was the start-up selected to launch this series of events, which will take place throughout the first three months of 2021
Last week we wanted to help you PREPARE for Clinical Trials. Today, learn how you can reach success in your product’s clinical development with our package CONDUCT.
As a results-driven company, HEMEX is dedicated to improving the lives of animals, people, and the planet. Today, we are really excited to formally announce the launch of a new series of HEMEX programs to drive change by welcoming cutting-edge ideas to the global Animal Health market.
Our portfolio company Opterion Health AG announced today the successful agreement of a EUR 8.4m Bridge Financing
Round. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I. Heartfelt congratulations on your success, Opterion!